Article
Genome-wide functional genomics screens identify therapeutic vulnerabilities for lymphangioleiomyomatosis
2019-06-27
Abstract excerpt
Lymphangioleiomyomatosis (LAM) is a rare lung disease marked by cystic destruction caused by invasive LAM cells harboring loss-of-function mutations in TSC2 that exhibit dysregulated mTORC1 signaling. Rapamycin, the only approved treatment, is not curative. Therapeutic discovery has been limited by inadequate cell and animal models due to the unknown LAM cell of origin. We report a novel TSC2 —/— human pluripot...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 6a795ebf-2c3a-57e0-80e8-7d9d32ad9227
- DOI
- 10.1101/683359
